Search

Search bills, members, committees and pages...

Sign In

H.R. 679

U.S. House•In House Committee

Summary

H.R. 679, to nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes, was introduced in the House on Jan 23, 2025 by Rep. Diana Harshbarger (R) with 18 co-sponsors. It was referred to Energy And Commerce, and last saw action on Jan 23, 2025: Referred to the House Committee on Energy and Commerce.

Record

Text

H.R. 679 has 18 co-sponsors.

hb679/introduced-in-house.txt
119 HR 679 IH: To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes.
 U.S. House of Representatives
 2025-01-23
 text/xml
 EN
 Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.
 I  119th CONGRESS  1st Session  H. R. 679  IN THE HOUSE OF REPRESENTATIVES   January 23, 2025   Mrs. Harshbarger  (for herself,  Mr. Hern of Oklahoma ,  Mr. Bost ,  Mrs. Miller of Illinois ,  Mr. Weber of Texas ,  Mr. Babin ,  Mr. Moolenaar ,  Mr. Webster of Florida ,  Mr. Baird ,  Mr. Higgins of Louisiana ,  Mr. Feenstra ,  Mr. Yakym ,  Mr. Biggs of Arizona ,  Mr. Palmer , and  Mr. Guest ) introduced the following bill; which was referred to the  Committee on Energy and Commerce    A BILL
To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes.
1.
Nullification of modifications to REMS for mifepristone
(a)
Nullification
The modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy under section 505–1 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355–1 ) for mifepristone are hereby nullified.
(b)
No substantially similar provisions
The Secretary of Health and Human Services (or any head of any office, department, or agency of the Department of Health and Human Services) shall not establish, implement, or enforce any provision of a risk evaluation and mitigation strategy under section 505–1 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355–1 ) for mifepristone that is substantially similar to any of the modifications nullified by subsection (a).

Tracker

The tracker indicates the progress of this legislation as it moves through the legislative process.

  1. Introduced2025-01-23
  2. Passed House
  3. Passed Senate
  4. Conference
  5. To President
  6. Became Law

CRS Summary

The summaries are the Congressional Research Service’s, one per stage. Read them in full.

Introduced in House Jan 23, 2025

hb679/introduced-in-house.md

Shown Here:
Introduced in House (01/23/2025)

Sponsors

Rep. Diana Harshbarger (R) sponsors H.R. 679, and 18 members have co-sponsored it, 14 of them from the day it was introduced.

Committees

H.R. 679 went before 1 committee: Energy and Commerce.

Energy and Commerce
Energy and Commerce
Referred To · Jan 23, 2025 · 1,636 Bills

Actions

H.R. 679 has taken 2 actions since Jan 23, 2025.

ChamberAction
Jan 23, 2025
House
Introduced in House
Jan 23, 2025
House
Referred to the House Committee on Energy and Commerce.Energy and Commerce Committee

Votes

H.R. 679 has not gone to a roll call.

Titles

H.R. 679 goes by 2 titles.

  • To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes. — Official Title as Introduced
  • To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes. — Display Title

Lobbying

3 clients hired 3 firms and 12 registered lobbyists who named H.R. 679 in 11 quarterly filings, 2025 to 2026. Reported under the Lobbying Disclosure Act; a filing’s income covers everything its registrant worked that quarter, so the amounts below are the filings’, not this bill’s.

Filed under Family issues/Abortion/Adoption, Government Issues, Constitution, Defense, Foreign Relations, Health Issues, Law Enforcement/Crime/Criminal Justice, Medicare/Medicaid.

Clients

Who paid to be heard, by how many filings named the bill.

ClientBusinessStateFirmsFilingsReported
SUSAN B ANTHONY LIST—Virginia16—
STUDENTS FOR LIFE ACTION—Virginia14—
HERITAGE ACTION FOR AMERICA—District of Columbia11—

Firms

Registrants who filed on the bill, by filings.

RegistrantClientsFilingsReported
SUSAN B ANTHONY LIST16—
STUDENTS FOR LIFE ACTION14—
HERITAGE ACTION FOR AMERICA11—

Lobbyists

Named on the filings that cite the bill.

LobbyistFirmsClientsFilings
AUTUMN CHRISTENSEN116
BILLY VALENTINE116
GWEN CHARLES116
JAMIE DANGERS116
JEREMY PILZ116
MARILYN MUSGRAVE116
MARJORIE DANNENFELSER116
KATIE GLENN DANIEL115
SAVANNA DERETICH114
GWEN ANDERSON111
MICHAEL ROGENMOSER111
SARAH URSPRUNG FELDPAUSCH)111

Filings

The documents themselves, on the Senate’s Lobbying Disclosure site, largest reported first.

ClientRegistrantPeriodReportedDocument
SUSAN B ANTHONY LISTSUSAN B ANTHONY LIST2025 first_quarter$600K1st Quarter - Report
SUSAN B ANTHONY LISTSUSAN B ANTHONY LIST2025 second_quarter$490K2nd Quarter - Report
SUSAN B ANTHONY LISTSUSAN B ANTHONY LIST2026 second_quarter$420K2nd Quarter - Report
SUSAN B ANTHONY LISTSUSAN B ANTHONY LIST2025 fourth_quarter$420K4th Quarter - Report
SUSAN B ANTHONY LISTSUSAN B ANTHONY LIST2026 first_quarter$380K1st Quarter - Report
SUSAN B ANTHONY LISTSUSAN B ANTHONY LIST2025 third_quarter$360K3rd Quarter - Report
HERITAGE ACTION FOR AMERICAHERITAGE ACTION FOR AMERICA2025 first_quarter$100K1st Quarter - Report
STUDENTS FOR LIFE ACTIONSTUDENTS FOR LIFE ACTION2025 fourth_quarter—4th Quarter - Report
STUDENTS FOR LIFE ACTIONSTUDENTS FOR LIFE ACTION2025 third_quarter—3rd Quarter - Report
STUDENTS FOR LIFE ACTIONSTUDENTS FOR LIFE ACTION2025 second_quarter—2nd Quarter - Report
STUDENTS FOR LIFE ACTIONSTUDENTS FOR LIFE ACTION2025 first_quarter—1st Quarter - Report

Classification

The Congressional Research Service files H.R. 679 under Health, one of its 31 policy areas, and gives it 4 legislative subjects.

CRS Subjects

CRS assigns every bill one policy area from its 31; H.R. 679’s is Health.

hr679/policy-areas.txt
HealthAgriculture and FoodAnimalsArmed Forces and National SecurityArts, Culture, ReligionCivil Rights and Liberties, Minority IssuesCommerceCongressCrime and Law EnforcementEconomics and Public FinanceEducationEmergency ManagementEnergyEnvironmental ProtectionFamiliesFinance and Financial SectorForeign Trade and International FinanceGovernment Operations and PoliticsHousing and Community DevelopmentImmigrationInternational AffairsLabor and EmploymentLawNative AmericansPublic Lands and Natural ResourcesScience, Technology, CommunicationsSocial WelfareSports and RecreationTaxationTransportation and Public WorksWater Resources Development

Legislative Subjects

H.R. 679 carries 4 of CRS’s legislative subjects, from Abortion to Prescription drugs.

hr679/subjects.txt
AbortionDrug safety, medical device, and laboratory regulationDrug therapyPrescription drugs

Source: congress.gov · legiscan.com